Literature DB >> 7561089

Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction.

R Merino1, D A Grillot, P L Simonian, S Muthukkumar, W C Fanslow, S Bondada, G Núñez.   

Abstract

The demise of B cell progenitors expressing functional IgM receptors for self appears to be the main mechanism by which B cell tolerance is accomplished. The genetic mechanisms that regulate the death process during this critical step of B cell development are still poorly understood. We have studied the regulation of apoptosis in WEHI-231 lymphoma cells after treatment with a panel of anti-IgM mAbs as an in vitro model of clonal B cell deletion. We showed that a product of bcl-x, Bcl-xL, can inhibit anti-IgM-induced apoptosis but not cell cycle arrest in a dose-dependent manner. Bcl-xL was efficient in protecting B cells from low but not high avidity anti-IgM mAbs. In contrast to that observed with Bcl-xL, CD40 stimulation was efficient in inhibiting both cell cycle arrest and apoptosis after IgM cross-linking regardless of the binding avidity of the anti-IgM Ab. Moreover, activation through IgM receptors but not CD40 induced up-regulation followed by rapid down-modulation of Bcl-xL. Thus, the capacity of Bcl-xL to modulate anti-IgM-induced apoptosis in WEHI-231 cells is highly dependent on the avidity of the Ab-IgM receptor interaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561089

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes.

Authors:  H H Lee; H Dadgostar; Q Cheng; J Shu; G Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells.

Authors:  Lijun Tan; Roland P Kwok; Abhishek Shukla; Malti Kshirsagar; Lili Zhao; Anthony W Opipari; J Rebecca Liu
Journal:  Cancer       Date:  2010-10-05       Impact factor: 6.860

3.  harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L).

Authors:  N Inohara; L Ding; S Chen; G Núñez
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

4.  Inhibition of B-cell death does not restore T-cell-dependent immune responses in CD40-deficient mice.

Authors:  Jesús Merino; Miguel A Díez; María Muñiz; Luis Buelta; Gabriel Núñez; Marcos López-Hoyos; Ramón Merino
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

5.  Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.

Authors:  R Liu; C Page; D R Beidler; M S Wicha; G Núñez
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

6.  Understanding apoptotic signaling pathways in cytosine deaminase-uracil phosphoribosyl transferase-mediated suicide gene therapy in vitro.

Authors:  P Gopinath; Siddhartha Sankar Ghosh
Journal:  Mol Cell Biochem       Date:  2008-12-14       Impact factor: 3.396

Review 7.  The role of germinal centers for antiviral B cell responses.

Authors:  M F Bachmann
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

8.  Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells.

Authors:  M Wu; M Arsura; R E Bellas; M J FitzGerald; H Lee; S L Schauer; D H Sherr; G E Sonenshein
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

Review 9.  Bcl-x and the regulation of survival in the immune system.

Authors:  T W Behrens; D L Mueller
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

10.  Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells.

Authors:  M Wu; H Lee; R E Bellas; S L Schauer; M Arsura; D Katz; M J FitzGerald; T L Rothstein; D H Sherr; G E Sonenshein
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.